vs

Side-by-side financial comparison of GRAFTECH INTERNATIONAL LTD (EAF) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $116.5M, roughly 1.9× GRAFTECH INTERNATIONAL LTD). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs -55.9%, a 75.3% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs -13.2%). Organogenesis Holdings Inc. produced more free cash flow last quarter ($34.8M vs $-39.3M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs -7.7%).

GrafTech International Ltd. is a manufacturer of graphite electrodes and petroleum coke, which are essential for the production of electric arc furnace steel and other metals. Headquartered in Brooklyn Heights, Ohio, it has manufacturing facilities in Calais, France;Pamplona, Spain; Monterrey, Mexico; and St. Marys, Pennsylvania.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

EAF vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.9× larger
ORGO
$225.6M
$116.5M
EAF
Growing faster (revenue YoY)
ORGO
ORGO
+91.4% gap
ORGO
78.1%
-13.2%
EAF
Higher net margin
ORGO
ORGO
75.3% more per $
ORGO
19.4%
-55.9%
EAF
More free cash flow
ORGO
ORGO
$74.0M more FCF
ORGO
$34.8M
$-39.3M
EAF
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
-7.7%
EAF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EAF
EAF
ORGO
ORGO
Revenue
$116.5M
$225.6M
Net Profit
$-65.1M
$43.7M
Gross Margin
-20.9%
Operating Margin
-33.6%
28.1%
Net Margin
-55.9%
19.4%
Revenue YoY
-13.2%
78.1%
Net Profit YoY
-31.6%
469.5%
EPS (diluted)
$-6.86
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EAF
EAF
ORGO
ORGO
Q4 25
$116.5M
$225.6M
Q3 25
$144.0M
$150.9M
Q2 25
$131.8M
$101.0M
Q1 25
$111.8M
$86.7M
Q4 24
$134.2M
$126.7M
Q3 24
$130.7M
$115.2M
Q2 24
$137.3M
$130.2M
Q1 24
$136.6M
$110.0M
Net Profit
EAF
EAF
ORGO
ORGO
Q4 25
$-65.1M
$43.7M
Q3 25
$-28.5M
$21.6M
Q2 25
$-86.9M
$-9.4M
Q1 25
$-39.4M
$-18.8M
Q4 24
$-49.5M
$7.7M
Q3 24
$-36.1M
$12.3M
Q2 24
$-14.8M
$-17.0M
Q1 24
$-30.9M
$-2.1M
Gross Margin
EAF
EAF
ORGO
ORGO
Q4 25
-20.9%
Q3 25
7.2%
Q2 25
0.0%
Q1 25
-1.5%
72.6%
Q4 24
-7.8%
75.5%
Q3 24
-9.2%
76.7%
Q2 24
2.9%
77.6%
Q1 24
-1.0%
73.9%
Operating Margin
EAF
EAF
ORGO
ORGO
Q4 25
-33.6%
28.1%
Q3 25
-3.6%
13.7%
Q2 25
-11.0%
-12.5%
Q1 25
-16.3%
-30.9%
Q4 24
-18.6%
8.1%
Q3 24
-20.1%
5.4%
Q2 24
-2.0%
-10.7%
Q1 24
-15.6%
-3.5%
Net Margin
EAF
EAF
ORGO
ORGO
Q4 25
-55.9%
19.4%
Q3 25
-19.8%
14.3%
Q2 25
-65.9%
-9.3%
Q1 25
-35.2%
-21.7%
Q4 24
-36.9%
6.1%
Q3 24
-27.6%
10.7%
Q2 24
-10.7%
-13.1%
Q1 24
-22.6%
-1.9%
EPS (diluted)
EAF
EAF
ORGO
ORGO
Q4 25
$-6.86
$0.31
Q3 25
$-1.10
$0.11
Q2 25
$-0.34
$-0.10
Q1 25
$-0.15
$-0.17
Q4 24
$-3.51
$0.05
Q3 24
$-1.40
$0.09
Q2 24
$-0.06
$-0.13
Q1 24
$-0.12
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EAF
EAF
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$93.7M
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$-259.6M
$300.1M
Total Assets
$1.0B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EAF
EAF
ORGO
ORGO
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$120.7M
$89.9M
Q1 24
$165.2M
$88.6M
Total Debt
EAF
EAF
ORGO
ORGO
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$929.5M
$62.3M
Q2 24
$928.2M
$63.8M
Q1 24
$926.9M
$65.2M
Stockholders' Equity
EAF
EAF
ORGO
ORGO
Q4 25
$-259.6M
$300.1M
Q3 25
$-194.4M
$255.1M
Q2 25
$-168.4M
$233.2M
Q1 25
$-105.3M
$242.9M
Q4 24
$-78.9M
$262.9M
Q3 24
$-9.0M
$278.5M
Q2 24
$16.2M
$263.5M
Q1 24
$37.6M
$278.0M
Total Assets
EAF
EAF
ORGO
ORGO
Q4 25
$1.0B
$598.7M
Q3 25
$1.1B
$509.8M
Q2 25
$1.1B
$461.1M
Q1 25
$1.2B
$467.4M
Q4 24
$1.2B
$497.9M
Q3 24
$1.1B
$446.3M
Q2 24
$1.2B
$443.2M
Q1 24
$1.2B
$458.5M
Debt / Equity
EAF
EAF
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
57.16×
0.24×
Q1 24
24.64×
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EAF
EAF
ORGO
ORGO
Operating Cash FlowLast quarter
$-20.9M
$39.4M
Free Cash FlowOCF − Capex
$-39.3M
$34.8M
FCF MarginFCF / Revenue
-33.7%
15.4%
Capex IntensityCapex / Revenue
15.8%
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-120.5M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EAF
EAF
ORGO
ORGO
Q4 25
$-20.9M
$39.4M
Q3 25
$24.7M
$3.1M
Q2 25
$-53.2M
$-32.9M
Q1 25
$-32.2M
$-19.9M
Q4 24
$-26.4M
$10.9M
Q3 24
$23.7M
$8.7M
Q2 24
$-36.9M
$4.7M
Q1 24
$-530.0K
$-10.2M
Free Cash Flow
EAF
EAF
ORGO
ORGO
Q4 25
$-39.3M
$34.8M
Q3 25
$18.4M
$844.0K
Q2 25
$-57.1M
$-36.5M
Q1 25
$-42.5M
$-23.6M
Q4 24
$-39.2M
$7.6M
Q3 24
$19.7M
$6.1M
Q2 24
$-43.8M
$2.9M
Q1 24
$-11.0M
$-12.4M
FCF Margin
EAF
EAF
ORGO
ORGO
Q4 25
-33.7%
15.4%
Q3 25
12.8%
0.6%
Q2 25
-43.3%
-36.1%
Q1 25
-38.0%
-27.2%
Q4 24
-29.2%
6.0%
Q3 24
15.1%
5.3%
Q2 24
-31.9%
2.2%
Q1 24
-8.1%
-11.3%
Capex Intensity
EAF
EAF
ORGO
ORGO
Q4 25
15.8%
2.1%
Q3 25
4.4%
1.5%
Q2 25
3.0%
3.6%
Q1 25
9.2%
4.2%
Q4 24
9.5%
2.7%
Q3 24
3.1%
2.2%
Q2 24
5.1%
1.4%
Q1 24
7.7%
2.0%
Cash Conversion
EAF
EAF
ORGO
ORGO
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EAF
EAF

Graphite Electrodes$107.0M92%
By Products And Other$9.4M8%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons